Study to Evaluate Efficacy and Safety of Wound Dressing Solution Containing EGF in Patients With Peptic Ulcers Bleeding — CEGP003

Peptic Ulcer Bleeding Clinical Trial

Official title:
Clinical Study to Evaluate Efficacy and Safety of "CEGP003(Wound Dressing Solution Containing EGF)" for Achieving Hemostasis and Protecting Ulcer in Patients With Acute Peptic Ulcer Bleeding: A Prospective, Randomized Trial

Status Completed

Clinical Trial Summary

This is a prospective, single-blinded, randomized study to evaluate the efficacy and safety of CEGP003 in patients with acute peptic ulcers bleeding, compared to endoscopic epinephrine injection therapy.

Clinical Trial Description

CEGP003 is wound dressing solution containing Hydroxyethyl-cellulose and EGF. Epidermal growth factor (EGF) stimulates cell growth and differentiation by binding to its receptor, which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a peptic ulcers bleeding. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03469167
Study type	Interventional
Source	CGBio Inc.
Contact
Status	Completed
Phase	N/A
Start date	October 15, 2014
Completion date	January 2, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02434978` - Doppler-guided Endoscopic Treatment in Peptic Ulcer Bleeding	N/A
Completed	`NCT01822600` - The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia	Phase 4
Completed	`NCT01591486` - Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding	N/A
Withdrawn	`NCT04407832` - Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy	N/A
Completed	`NCT01591083` - The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers	Phase 4
Completed	`NCT02152904` - Risk Factors of Rebleeding After Peptic Ulcer Bleeding: a Nationwide Cohort Study	N/A